Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) had its price objective reduced by HC Wainwright from $27.00 to $20.00 in a report issued on Thursday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 161.44% from the stock's previous close.
ORIC has been the topic of a number of other reports. Wedbush restated an "outperform" rating on shares of Oric Pharmaceuticals in a report on Tuesday. Wells Fargo & Company decreased their price target on shares of Oric Pharmaceuticals from $25.00 to $23.00 and set an "overweight" rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an "overweight" rating in a report on Wednesday, October 14th. Stifel Nicolaus boosted their price objective on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the company a "buy" rating in a research report on Monday, October 26th. Finally, Wall Street Zen raised shares of Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 25th. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $20.58.
View Our Latest Research Report on ORIC
Oric Pharmaceuticals Stock Down 4.4%
NASDAQ ORIC opened at $7.65 on Thursday. Oric Pharmaceuticals has a fifty-two week low of $7.23 and a fifty-two week high of $14.68. The stock has a market cap of $792.95 million, a price-to-earnings ratio of -5.24 and a beta of 1.23. The business has a fifty day moving average of $11.26 and a 200-day moving average of $10.96.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.05). As a group, analysts anticipate that Oric Pharmaceuticals will post -1.53 EPS for the current year.
Insider Buying and Selling
In related news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $1,432,952 in the last ninety days. Corporate insiders own 5.70% of the company's stock.
Institutional Trading of Oric Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC grew its holdings in Oric Pharmaceuticals by 33.5% in the third quarter. Algert Global LLC now owns 1,621,908 shares of the company's stock valued at $21,847,000 after purchasing an additional 406,615 shares during the period. New York State Common Retirement Fund increased its position in Oric Pharmaceuticals by 43.4% during the third quarter. New York State Common Retirement Fund now owns 26,429 shares of the company's stock worth $356,000 after purchasing an additional 8,000 shares during the last quarter. Quarry LP increased its position in Oric Pharmaceuticals by 23.9% during the third quarter. Quarry LP now owns 20,848 shares of the company's stock worth $281,000 after purchasing an additional 4,018 shares during the last quarter. Bellevue Group AG acquired a new position in Oric Pharmaceuticals during the third quarter worth approximately $75,000. Finally, Toronto Dominion Bank purchased a new position in Oric Pharmaceuticals during the third quarter worth approximately $5,253,000. Hedge funds and other institutional investors own 95.05% of the company's stock.
About Oric Pharmaceuticals
(
Get Free Report)
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oric Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.
While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.